Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

Author's Avatar
Nov 20, 2018
Article's Main Image

Topline results show reduction in LGCS, a standard measure in this indication, at 3 months from baseline

PR Newswire